Radioactive injection targets Hard-to-Treat tumors in new trial

NCT ID NCT06398444

Recruiting now Disease control Sponsor: Sinotau Pharmaceutical Group Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests a radioactive drug called Lutetium-177 oxodotreotide in 74 people with advanced neuroendocrine tumors that have spread and are growing despite other treatments. The drug is designed to seek out and deliver radiation directly to tumor cells. Researchers are checking safety and how well it shrinks or controls the tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lutetium-177 oxodotreotide (a radioactive drug that targets tumor cells)
What this could lead to: If successful, this could provide a new treatment option to shrink or slow growth of advanced neuroendocrine tumors that have spread and are no longer responding to other therapies.
What could go wrong: This is an early-to-mid stage trial with only 74 participants and no comparison group, so results may not be definitive. Radioactive treatment can cause side effects like kidney or bone marrow damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED NEUROENDOCRINE NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine neoplasm paraganglioma pheochromocytoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED NEUROENDOCRINE NEOPLASM

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.